IgA-positive Versus IgA-negative Immune Complex Vasculitis
NCT ID: NCT01815190
Last Updated: 2015-12-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
300 participants
OBSERVATIONAL
2011-01-31
2016-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
In some cases vasculitis also affects systemic organs, such as the kidneys and the intestine.
When the immune complexes contain immunoglobulin class A (IgA) and when there is systemic involvement, the disease has been referred to as Henoch Schönlein purpura.
When there are no signs of systemic involvement, the disease has been referred to as cutaneous leukocytoclastic angiitis.
The investigators hypothesize that palpable purpura with predilection for lower legs is a pathognomonic clinical sign for immune complex vasculitis in both IgA vasculitis and IgA-negative vasculitis, but that only the presence of IgA in immune complexes is likely to be associated with systemic involvement and therefore warrants more extensive diagnostic procedures Vice versa the investigators postulate that the presence of IgG or IgM without IgA in immune complexes excludes systemic involvement The investigators also want to investigate to which of the 2 groups patients with palpable purpura and negative immunofluorescence should be assigned.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
IgA-positive vasculitis
Patients with immune complex vasculitis who show perivascular deposits of IgA
No interventions assigned to this group
IgA-negative vasculitis
Patients with immune complex vasculitis who show no perivascular deposits of IgA
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* clinically palpable purpura
Exclusion Criteria
* relevant data missing in file
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital Muenster
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Cord Sunderkötter
Professor Dr
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Cord Sunderkoetter, Prof Dr MD
Role: PRINCIPAL_INVESTIGATOR
Department of Dermatology, Univ Hospital of Muenster
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Dermatology, Univ hospital of Muenster
Münster, , Germany
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Ilka Herrgott, MD
Role: CONTACT
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2011-040-f-S
Identifier Type: -
Identifier Source: org_study_id